FutureMeds Appoints Gemma Whiteley as Managing Director of FutureMeds @home

FutureMeds has appointed Gemma Whiteley as Managing Director of FutureMeds @home, strengthening its decentralised clinical trial offering as the company expands tailored, patient-focused solutions for Sponsors and CROs. 

FutureMeds has appointed Gemma Whiteley as Managing Director of FutureMeds @home, part of a company-wide push to increase the impact of decentralised and hybrid clinical trials. Under her leadership, FutureMeds @home will accelerate service expansion, deepen client partnerships, and elevate patient access to clinical research. 

A key element of this strategy is the recently announced strategic partnership with GooseBerry Research, a U.S.-based in-home clinical trial specialist. The collaboration combines GooseBerry’s home nursing capabilities in the U.S. with FutureMeds’ infrastructure across Europe, to deliver rare disease and paediatric trials with improved patient access, stronger site engagement, enhanced workflows, and high standards of compliance. 

Gemma will lead the next phase of growth for the division, advancing FutureMeds’ strategy to deliver tailored, patient-focused solutions for Sponsors and CROs. 

“Gemma’s leadership marks the start of an exciting next chapter for FutureMeds @home. With her deep expertise in site-based research and HomeCare delivery, she is ideally placed to shape the future of decentralised trials and help redefine how studies are delivered globally. I am convinced she will drive notable progress in making research more accessible, patient-focused, and impactful for Sponsors worldwide.” 

— Iwona Tongbhoyai, Chief Client Solutions Officer  

In her new role, Gemma is tasked with expanding FutureMeds @home’s service portfolio and footprint, building sustainable client partnerships, guiding clients, and increasing the adoption of fit-for-purpose DCT solutions. She will also focus on enhancing the level of integration of home-based services with FutureMeds’ network of dedicated clinical research sites, creating an even more powerful platform for flexible hybrid trials. 

Collaboration with FutureMeds’ U.S. partner, GooseBerry Research, will also be a priority, enabling clients to access truly global, decentralised and hybrid solutions. 

“I can't think of a more exciting time to join Futuremeds and lead Futuremeds @home into the next exciting stage of growth and development. Stepping into this pivotal role, I know I'll be joining a talented and highly motivated team. I'm looking forward to leveraging my experience and passion for clinical research, to support customers and sites to find the best solutions for patients and participants at a truly global level. Together we can widen accessibility to trials and drive the best quality evidence for the treatments of the future.” 

— Gemma Whiteley, Managing Director of FutureMeds @home 

Gemma has built her career over more than 15 years in clinical research, beginning in the NHS before moving into senior global leadership roles across strategy, delivery, and operations. Most recently, she worked at AES (part of Thermo Fisher Scientific) as Vice President of Feasibility and Project Delivery. Here, she brought together her experience in service transformation, stakeholder engagement, and clinical trial delivery to strengthen teams, modernise ways of working, and ensure research truly benefits patients. 

Known for her collaborative style and focus on people, Gemma is passionate about creating high-performing teams and encouraging innovation at every level. She thrives on tackling complex challenges, driving continuous improvement, and supporting others to succeed.